194 reports of this reaction
2.1% of all NASAL reports
#9 most reported adverse reaction
PYREXIA is the #9 most commonly reported adverse reaction for NASAL, manufactured by BEST CHOICE (VALU MERCHANDISERS COMPANY). There are 194 FDA adverse event reports linking NASAL to PYREXIA. This represents approximately 2.1% of all 9,176 adverse event reports for this drug.
Patients taking NASAL who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is a less commonly reported adverse event for NASAL, but still significant enough to appear in the safety profile.
In addition to pyrexia, the following adverse reactions have been reported for NASAL:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 194 FDA reports for NASAL. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 2.1% of all adverse event reports for NASAL, making it a notable side effect.
If you experience pyrexia while taking NASAL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.